NCCN 2026 Annual Congress: Hematologic Malignancies™

New York, NY US
September 18, 2026 to September 19, 2026

The NCCN 2026 Annual Congress: Hematologic Malignancies™ highlights new and emerging therapeutic agents, updates to the NCCN Guidelines®, and practical management strategies for hematologic malignancies.

Target Audience

This program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician associates, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

The goal for NCCN Continuing Education is to enhance patient care and outcomes by improving the competence and performance of clinicians.

The goal of the NCCN 2026 Annual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

  • Apply the current standards of oncology care and key updates in the NCCN Guidelines® to optimize the management of patients with various hematologic malignancies.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.

Click here to view individual session learning objectives. 

Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • BeOne
  • Blueprint Medicines, a Sanofi company
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Novartis
  • PharmaEssentia

Supported by an independent medical education grant from AbbVie.

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary

Available credit: 
  • 14.00 AAPA Category 1 CME credit
  • 14.00 ACPE contact hours
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 ANCC contact hours
    • 12.00 ANCC Pharmacology Contact Hours
  • 14.00 Participation
Course opens: 
09/19/2026
Course expires: 
12/04/2026
Event starts: 
09/18/2026 - 1:00pm EDT
Event ends: 
09/19/2026 - 4:00pm EDT
Add to calendar: 
Friday, September 18, 2026
All times are listed as Eastern Daylight Time (UTC/GMT -4)
**Offers pharmacotherapeutic contact hours for nurses.
 
1:00 – 1:05 PM     
Opening Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
 
1:05 – 1:35 PM
Transforming the Management of Acute Lymphoblastic Leukemia**
Benjamin Tomlinson, MD, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute
 
1:35 – 2:05 PM
Oral Targeted Therapies in Relapsed/Refractory Acute Myeloid Leukemia**
Kateryna Fedorov, MD, Vanderbilt-Ingram Cancer Center
 
2:05 – 2:35 PM
Chronic Myeloid Leukemia: De-Escalation of TKI Therapy**
Vivian G. Oehler, MD, Fred Hutchinson Cancer Center
 
2:35 – 3:05 PM
Managing Toxicities of Outpatient Oral Therapies for Chronic Myeloid Leukemia**
Jenna Moran, MSN, FNP-BC, Mass General Cancer Institute
 
3:25 – 3:55 PM
The Role of Clonal Hematopoiesis in Hematologic Malignancies**
Amy E. DeZern, MD, MHS, Johns Hopkins Kimmel Cancer Center
 
3:55 – 5:25 PM
Evolving Treatment Strategies in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma**
Natalie S. Callander, MD, University of Wisconsin Carbone Cancer Center
Beth Faiman, PhD, MSN, APRN-BC, TCTCN, AOCN, FAAN, FAPO, Cleveland Clinic Taussig Cancer Institute
Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center
Shaji K. Kumar, MD, Mayo Clinic Comprehensive Cancer Center
 
5:25 – 5:30 PM        
Closing Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
 
Saturday, September 19, 2026
 
8:00 – 8:05 AM
Opening Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
 
8:05 – 9:05 AM
Outpatient Administration of Bispecific Antibodies and CAR T-Cell Therapies**
Marcos J. de Lima, MD, The Ohio State University Comprehensive Cancer Center
– James Cancer Hospital and Solove Research Institute
Jacqueline Dela Peña, PharmD, BCOP, Memorial Sloan Kettering Cancer Center
Tara M. Graff, DO, MS, Mission Cancer and Blood, University of Iowa Health Care 
Kathy Mooney, MSN, RN, ACNS-BC, TCTCN, OCN, Johns Hopkins Kimmel Cancer Center
            
9:05 – 10:20 AM
Managing Toxicities of Bispecific Antibodies and CAR T-Cell Therapies in the Outpatient Setting**
Carissa Laudati, MSN, FNP-BC, OCN, Memorial Sloan Kettering Cancer Center
Olalekan Oluwole, MBBS, MPH, Vanderbilt-Ingram Cancer Center
Salyka M. Sengsayadeth, MD, Vanderbilt-Ingram Cancer Center
Katie Tobon, PharmD, BCOP, Moffitt Cancer Center
 
10:40 – 11:10 AM
Working Toward Unified Classification of Hematolymphoid Malignancies
Pallavi Kanwar Galera, MD, Memorial Sloan Kettering Cancer Center
 
11:10 – 11:40 AM
Current and Emerging Treatment Options for Peripheral T-Cell Lymphomas**
Stefan K. Barta, MD, MS, Abramson Cancer Center at the University of Pennsylvania
 
12:40 – 1:25 PM
Chronic Lymphocytic Leukemia: Navigating First-Line and MRD-Guided Treatment Options**
Matthew J. Cortese, MD, MPH, Roswell Park Comprehensive Cancer Center
 
1:25 – 1:55 PM
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma**
Peter A. Riedell, MD, The UChicago Medicine Comprehensive Cancer Center
 
2:10 – 2:40 PM
Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma**
Jeremy Abramson, MD, MMSc, Mass General Brigham Cancer Institute
 
2:40 – 3:10 PM
Update on the Diagnosis and Management of Marginal Zone Lymphomas**
C. Babis Andreadis, MD, MSCE, UCSF, Helen Diller Family Comprehensive Cancer Center
 
3:10 – 3:55 PM
Collaborative Strategies for Optimizing Small-Volume Drug Delivery**
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN, Johns Hopkins Kimmel Cancer Center
Grace H. Pak, PharmD, MHA, BCPS, Johns Hopkins Kimmel Cancer Center
 
3:55 – 4:00 PM
Closing Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
 
On-Demand Sessions
 
Individualizing Treatment for Patients with Waldenström Macroglobulinemia**
Shayna Sarosiek, MD, Dana-Farber Cancer Institute | Harvard Medical School

Erdheim-Chester Disease: The Role of Molecular Testing in Treatment Planning
Gaurav Goyal, MD, O'Neal Comprehensive Cancer Center at UAB

The Evolving Treatment Landscape in Myeloproliferative Neoplasms**
Andrew T. Kuykendall, MD, Moffitt Cancer Center

Advances in Systemic Mastocytosis**
Lindsay Rein, MD, Duke Cancer Institute
 
Treating Adult Patients with Burkitt Lymphoma**
Sunita D. Nasta, MD, Abramson Cancer Center at the University of Pennsylvania

Psychosocial Support for Adolescent and Young Adult Patients with Hematologic Malignancies
Jeanelle Folbrecht, PhD, City of Hope National Medical Center
New York Marriott Marquis
1535 Broadway
New York, NY 10036
United States
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Click here to download the faculty disclosures for this program. 

image
Joint Accreditation
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 14.0 contact hours.

This program offers 12.00 pharmacotherapeutic contact hours for nurses. Refer to the Schedule to view eligible sessions.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 14.0 contact hours (1.40 CEUs) of continuing education credit. UAN: JA4008196-0000-26-079-L01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 14.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 14.0 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, NCCN 2026 Hematologic Malignancies Congress has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
 
ABMS Lifelong Learning CME Activity
Radiology
 
Permission to Upload Credits
For ABIM and ABPath MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records. By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Available Credit

  • 14.00 AAPA Category 1 CME credit
  • 14.00 ACPE contact hours
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 ANCC contact hours
    • 12.00 ANCC Pharmacology Contact Hours
  • 14.00 Participation
Please login or register to take this course.

To claim your credits, log in with the same email address you used for program registration.

CE/MOC credit should be claimed for the Congress as a whole, not session by session. You may claim credit for the Congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days after the live congress.)

Pharmacists: you must complete all requirements for credit by Tuesday, November 3, 2026.

Tracking Your Session Attendance: Download the PDF here to help keep track of your session attendance. The worksheet is for your reference only. Completion of this worksheet is not required to claim continuing education credit.

Required Hardware/software

To complete this activity, you will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader for certificate viewing/printing